3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma

Autor:	Carola Berking, Tim Demuth, S. Jaeger, K. Carter, V. Antona, Anja Gesierich, E. Muñoz, Wilson H. Miller, R. Dummer, Shahneen Sandhu, Jessica C. Hassel, X. Cui, O. Esposito, G. Caponigro, P.A. Ascierto, R. Radhakrishnan
Rok vydání:	2015
Předmět:	Oncology Cancer Research medicine.medical_specialty Adult patients business.industry Melanoma Locally advanced Binimetinib medicine.disease chemistry.chemical_compound chemistry Open label study Internal medicine medicine business
Zdroj:	European Journal of Cancer. 51:S667-S668
ISSN:	0959-8049
DOI:	10.1016/s0959-8049(16)31828-7
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f35871fe43f5ba12e96e72ef3ade3f24 https://doi.org/10.1016/s0959-8049(16)31828-7 Zobrazit plný text záznamu Full Text from ScienceDirect